Melanoma (Skin) Clinical Trial
Official title:
Melanoma Lifestyle Study
RATIONALE: Gathering information about vitamin D supplementation and sun exposure in
patients with melanoma may help doctors learn more about the disease and find what may
affect cancer relapse.
PURPOSE: This clinical trial is studying vitamin D supplementation and sun exposure in
patients who have undergone surgery for stage IB, stage II, or stage IIIA melanoma.
OBJECTIVES:
- To examine the findings of the pilot study, that vitamin D supplementation in
combination with vitamin D receptor (VDR) polymorphisms protects from late relapse
(after 3 years) in patients who have had melanoma.
- To investigate the effects of vitamin D supplement dosage in reducing the risk of late
relapse.
- To examine if vitamin D supplementation in combination with particular VDR
polymorphisms protects from early relapse (before 3 years).
- To examine if serum levels of vitamin D correlate with risk of relapse in groups of
patients with different VDR polymorphisms.
- To examine the effect of vitamin supplementation and VDR status on time to relapse and
survival in these patients.
- To examine other factors that may affect risk of relapse by assembling a tissue
(genomic DNA and serum) resource.
- To investigate the effect of exposure to incidental drugs, such as statins, on risk of
relapse in these patients.
OUTLINE: Patients are stratified according to disease relapse in the past 5 years (yes vs
no).
Patients are asked to complete a food frequency questionnaire focusing on vitamin D and the
following area: supplementation of diet with vitamins/fish oil and duration of use; sun
exposure and sunscreen-use per decade prior to and after diagnosis. Patients are also asked
to provide a blood sample for serum and DNA analysis. Consenting patients are also tagged
with the Office of National Statistics to allow passive follow up.
Stored tissue from the patient's primary melanoma may be used to corroborate research
findings using immunohistochemistry or studies of gene expression, polymorphism, or
mutation.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
| Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
| Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
| Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
| Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
| Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
| Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
| Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
| Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
| Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
| Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
| Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
| Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
| Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |